Delivery Method: Via Electronic Mail – Delivery and Read Receipt Requested Reference #: 320-26-07 Product: Drugs Recipient: Recipient Name Mr. Robert Kibbe Recipient Title President and […]

On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute myeloid leukemia with […]

Delivery Method: VIA UPS Reference #: 320-25-115 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Prakash C. Purohit Recipient Title President/Owner Naturich Cosmetique Labs 2505 Merritt […]

[10-23-2025] The Food and Drug Administration is advising consumers not to purchase or use SPARTAN, a product promoted and sold for male sexual enhancement on various […]

On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib […]

76 218492 Prucalopride Tablets Novitium Pharma LLC Motegrity Tablets 12/26/2024 For the treatment of chronic idiopathic constipation in adults 75 215971 Deutetrabenazine Tablets Aurobindo Pharma Limited […]

FDA’s role in drug recalls A recall may be recommended or requested by FDA or initiated voluntarily at any time by a company. FDA’s role in […]

For Immediate Release: October 23, 2025 The U.S. Food and Drug Administration today made public filing checklists used internally by Center for Drug Evaluation and Research […]

S = Susceptible; I = Intermediate; R = Resistant a. Susceptibility interpretive criteria are based on a dose of 6 grams fosfomycin every 8 hours by […]